Form 4: Agios Pharmaceuticals Director Maykin Ho Reports Stock Transactions

Director Maykin Ho reports acquisition and disposal of Agios Pharmaceuticals common stock and restricted stock units on June 13, 2024.

Summary

• On June 13, 2024, Maykin Ho, a director of Agios Pharmaceuticals, reported transactions involving the company's common stock and restricted stock units.
• Ho acquired 3,388 shares of common stock and disposed of 3,388 shares.
• Following these transactions, Ho beneficially owns 14,912 shares of common stock.
• The restricted stock units, granted on June 13, 2023, vested in full on June 13, 2024, and represent a contingent right to receive one share of Agios Pharmaceuticals common stock each.
• Vested shares will be delivered to Ho within three business days after vesting.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing detailing stock transactions by a company director. It doesn't inherently convey positive or negative sentiment, but rather provides factual information.

Future Outlook

The vested shares from the restricted stock units will be delivered to the reporting person within three business days after such shares become vested.

Industry Context

This Form 4 filing is a routine disclosure required by the SEC for corporate insiders, providing transparency into their trading activities in the company's stock. It's a standard practice for directors and officers to receive and vest stock options or restricted stock units as part of their compensation.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in beneficial ownership.
• The vesting of restricted stock units is part of the director's compensation package, impacting their overall remuneration.

Key Dates